EP0644754A4 - Substance that can stop bleeding in surgical, medical and dental uses/substance powder 001 that can stop bleeding during surgery, after surgery, medicine, dentistry or any bleeding due to any causes. - Google Patents

Substance that can stop bleeding in surgical, medical and dental uses/substance powder 001 that can stop bleeding during surgery, after surgery, medicine, dentistry or any bleeding due to any causes.

Info

Publication number
EP0644754A4
EP0644754A4 EP92901379A EP92901379A EP0644754A4 EP 0644754 A4 EP0644754 A4 EP 0644754A4 EP 92901379 A EP92901379 A EP 92901379A EP 92901379 A EP92901379 A EP 92901379A EP 0644754 A4 EP0644754 A4 EP 0644754A4
Authority
EP
European Patent Office
Prior art keywords
bleeding
powder
surgery
substance
stop
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP92901379A
Other languages
German (de)
French (fr)
Other versions
EP0644754A1 (en
Inventor
Leslie Binshyang Soong
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of EP0644754A1 publication Critical patent/EP0644754A1/en
Publication of EP0644754A4 publication Critical patent/EP0644754A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365Lactones
    • A61K31/375Ascorbic acid, i.e. vitamin C; Salts thereof

Definitions

  • P ⁇ TN ⁇ IK 1971 stated that the concentration of ascorbic acid has been reported as decrea ⁇ ingvith age in the rat eye lens, adrenal, brain, testis, and blood.
  • Purpura (extensive bruising ) and hemorrhages under the tongue are common in elderly people. Tattersal and Seville 1950 reported purpura in 60 out of 009 elderly patients admitted to hospital; the bruises were most commonly seen on the anterior aspects of their arms and fore- ornv. and on tr.e backs of their hands, noth p-it ientj.
  • THIS invention pertains to the field of disorder of hem ⁇ stasis, which is further classified into evaluation of hemostatic function, platelet disorders, coagulation factor disorders and thromboe bolic disorders.
  • the blood coagulation mechanism of ascorbic acid which - was administered topically does not fall into either intrinsic or extrinsic pathway cascade, since it works the same for hemosta ⁇ i ⁇ in normal situation as in chronic- hepatitis, colon cancer, and hemophilia patients in whom the coagulation factors 2, 7, 9, 10 in the liver dise and factor 8 or 9 in the hemophilia A or B cannot be produ
  • the present methods available to stop bleeding in surger are cautery, epinephrine injection, pressure and some fiber foam.
  • the cautery can cause tissue necrosis in some cases.
  • the epinephrine, pressure and fiber foam can not work for bleeding tendency patients, and fiber foam can cause tissue hemotoma, nor can they work for diffuse capillary bleeding and oozing, while ascorbic acid does not cause any tissue necrosis and works particularly >r* ⁇ ⁇ for diffuse capillary bleeding and any traditionally un ⁇ controllable bleeding tendency patients such as for patient with liver diseases, hemophilia and rectal anal cancer and for postoperation bleeding tendency nf the kinds of aforementioned patients.
  • the ascorbic acid can facilitate wound healing also ( Oral Surg 1982 Mar: 53(3): 231-6 ) by increasing type 1 procollagen mRN ⁇ in the regulation of collagen synthesis ( Atherosclerosis 1982 Jan: 41(1): 15-9 ) (d) Explanation of Invention / Summary.
  • Substance powder 001 represents ascorbic acid powder that i c obtained by grinding the vitamin C tablets into powder. This powder has a very potent hemostatic action to stop bleeding wnen spraying it topically on the bleeding area for any with the blood, the black tar gel like material is formed, and later becomes solid. The amount of the powder that is needed to react completely with the blood is proportional to the amount of the blood that comes out of the blood vessels. In rats, one capillary, one venous and one femoral artery bleeding were stanched within one second, if sufficien amounts of the powder of ascorbic acid were applied. The arte bleeding needs much more this powder of interest.
  • test tube conditions it requires 0.1568 g of this substance powde to coagulate ( make the blood black and not move in the tube 1 ml of human blood in 6 minutes.
  • This is the same for normal colon cancer a d hemophilia patients; 1 ml of normal blood needs 0.1568 g of ascorbic acid powder, 1 ml of colon cancer blood needs 0.1568 g of ascorbic acid powder, and 1 ml of hemophilia blood needs 0.1568 g of ascorbic acid powder.
  • Suff substance powder 001 is particularly useful to help stop blee in the case of diffuse capillary oozing and mistakenly cut of artery or arteries that cannot be found during massive bleedi bleeding so as to save the patients' lives.
  • the present methods available to stop bleeding in surgery as previously mentioned are cautery, epinephrine injection, press and some fiber foam.
  • the cautery can cause tissue necrosis in some cases.
  • the epinephrine, pressure and fiber foam can not cannot work for bleeding tendency and diffuse capillary oozi patients, while ascorbic acid powder does not cause any tissu necrosis and particularly works well for diffuse capillary bl and oozing and any traditionally uncontrollable bleeding tend patients such as for patients with liver diseases, hemophilia and colon rectal or other cancer bleeding conditions and for postoperation bleeding tendency of the kinds of aformentioned patients.
  • the ascorbic acid also facilitate wound healing ( O Surg.
  • the substance powder ool is made by grinding the pure vitamin C tablets into powder. Application of this powder topically to the bleeding area is betber'by spraying the powder topically on the bleeding area.
  • the amount of vitamin C powder needed to spray is proportional to the amount of blood coming out of the vessels. In test tube conditions, it requires 0.1568 g of this * vitamin C powder to coagulate 1 ml of human blood. This ⁇ i ⁇ the same for normal, liver diseases, cancer, and hemophilia patients. The black coagulation takes place in 6 minutes by shaking the test tube. The description of this s ⁇ tuation is made in the evidence of animal ( rats ) experiments and clinical evidence as follows: (f) Rats Experiments
  • Sufficient substance powder 001 can stop massive bleeding of femoral artery within one second when femoral artery is cut off.
  • Photograph # 1 massive bleeding when the femoral artery is cut off
  • Photogrph # 2 bleeding stops within one second when sufficient powder of interest was poured topically into the bleeding area, in this case of massive active bleeding T did pouring instead of spraying.
  • the amount of the powder needed is proportional to the amount of blood coming out of the vessel. It varies with the rats. Usually 0.1344 g is sufficient to stop bleeding for the femoral artery of the rat which is cut off vithin one second.
  • the black tar gel like material was formed in one second as soon as the powder contacts with the blood .
  • This powder also help stop massive bleeding in surgery, no matter what kind of diseases the patients suffered from.
  • tube con il.ion as mentioned previously, ] m ] of human b 1 .nor! requires 0.15C>fl q of powder to form Ma ⁇ -k bloori coa- qulatton by shaking the tube with hand or ⁇ color machine.

Abstract

A method for stopping bleeding is described. The method entails applying to the site of bleeding powdered Vitamin C.

Description

SUBSTANCE THAT CAN STOP BLEEDING IN SURGICAL,MEDICAL AND DENTAL
USES/SUBSTANCE POWDER 001 THAT CAN STOP BLEEDING DURING SURGERY,
AFTER SURGERY, MEDECINE, DENTISTRY OR ANY BLEEDING DUE TO ANY CAUSES
SPECIFICATION OF INVENTION
(a) Title of the Invention.
The substance powder 001 that can stop (stanch) bleeding in surgical, postsurgical , medical and dental uses or any bleeding due to any causes by topical administration or the substance powder 001 that has very potent hemoεtatic action can be administered topically to stop bleeding during surgery, after surgery, medicine by inqestion, dental surgery, extraction of teeth, and any injury or due to any causes for any normal and pathological ρpr«?nn«?.
(b) Cross-References to Related Applications.
The early literature on scurvy due to vitamin r riefioeπry wa reviewed by Bourne in 1944, he shoved hieroglyphs from Egypti papyri as convincing evidence that this disease, charaterized by bleeding gums and hemorrhages in the skin, existed about 3000 years ayo. Λ sudden pain seized their feet, and leys; immediately afterwards the gums and teeth were attacked by a sort of gangrene. The bones of the legs become horribly black. The legs shrivelled up and became covered with black spots. It as a sure sign of death when the nose began to bleed. ( Hourne, G,H, 1944, Proc. K. Spc. Me . , 37, 51? ) PΛTNΛIK 1971 stated that the concentration of ascorbic acid has been reported as decreaεingvith age in the rat eye lens, adrenal, brain, testis, and blood. ( Patnaik, B.K. 1971, Gerontologia , 17, 122 ) Purpura (extensive bruising ) and hemorrhages under the tongue are common in elderly people. Tattersal and Seville 1950 reported purpura in 60 out of 009 elderly patients admitted to hospital; the bruises were most commonly seen on the anterior aspects of their arms and fore- ornv. and on tr.e backs of their hands, noth p-it ientj. an7 the controls were ascorbate deficient, as ju ged by ascorr.:r acid loading tests; skin biopsies from those vith purσura sho ed degeneration of tne collagen fibres rf the derππs. Tatttisa (c) Background of the Invention.
(1) THIS invention pertains to the field of disorder of hemσstasis, which is further classified into evaluation of hemostatic function, platelet disorders, coagulation factor disorders and thromboe bolic disorders. However, the blood coagulation mechanism of ascorbic acid which - was administered topically does not fall into either intrinsic or extrinsic pathway cascade, since it works the same for hemostaεiε in normal situation as in chronic- hepatitis, colon cancer, and hemophilia patients in whom the coagulation factors 2, 7, 9, 10 in the liver dise and factor 8 or 9 in the hemophilia A or B cannot be produ (2) The present methods available to stop bleeding in surger are cautery, epinephrine injection, pressure and some fiber foam. The cautery can cause tissue necrosis in some cases. The epinephrine, pressure and fiber foam can not work for bleeding tendency patients, and fiber foam can cause tissue hemotoma, nor can they work for diffuse capillary bleeding and oozing, while ascorbic acid does not cause any tissue necrosis and works particularly >r*\ \ for diffuse capillary bleeding and any traditionally un¬ controllable bleeding tendency patients such as for patient with liver diseases, hemophilia and rectal anal cancer and for postoperation bleeding tendency nf the kinds of aforementioned patients. The ascorbic acid can facilitate wound healing also ( Oral Surg 1982 Mar: 53(3): 231-6 ) by increasing type 1 procollagen mRNΛ in the regulation of collagen synthesis ( Atherosclerosis 1982 Jan: 41(1): 15-9 ) (d) Explanation of Invention / Summary.
Substance powder 001 represents ascorbic acid powder that ic obtained by grinding the vitamin C tablets into powder. This powder has a very potent hemostatic action to stop bleeding wnen spraying it topically on the bleeding area for any with the blood, the black tar gel like material is formed, and later becomes solid. The amount of the powder that is needed to react completely with the blood is proportional to the amount of the blood that comes out of the blood vessels. In rats, one capillary, one venous and one femoral artery bleeding were stanched within one second, if sufficien amounts of the powder of ascorbic acid were applied. The arte bleeding needs much more this powder of interest. In the test tube conditions, it requires 0.1568 g of this substance powde to coagulate ( make the blood black and not move in the tube 1 ml of human blood in 6 minutes. This is the same for normal colon cancer a d hemophilia patients; 1 ml of normal blood needs 0.1568 g of ascorbic acid powder, 1 ml of colon cancer blood needs 0.1568 g of ascorbic acid powder, and 1 ml of hemophilia blood needs 0.1568 g of ascorbic acid powder. Suff substance powder 001 is particularly useful to help stop blee in the case of diffuse capillary oozing and mistakenly cut of artery or arteries that cannot be found during massive bleedi bleeding so as to save the patients' lives.
The present methods available to stop bleeding in surgery as previously mentioned are cautery, epinephrine injection, press and some fiber foam. The cautery can cause tissue necrosis in some cases. The epinephrine, pressure and fiber foam can not cannot work for bleeding tendency and diffuse capillary oozi patients, while ascorbic acid powder does not cause any tissu necrosis and particularly works well for diffuse capillary bl and oozing and any traditionally uncontrollable bleeding tend patients such as for patients with liver diseases, hemophilia and colon rectal or other cancer bleeding conditions and for postoperation bleeding tendency of the kinds of aformentioned patients. The ascorbic acid also facilitate wound healing ( O Surg. 1982 Mar: 53 (3j: 231-6 ) by increasing type 1 procollag mRNA in the regulation of collagen synthesis ( Atherosclerosis 1982 Jan: 41(1): 15-9 ) and when the vitamin C is absorbed into the system, it is good for health by making the leucocytes stronge and slowing the aging process etc, ( Patnaik and Kanungo 1964, Gerontologia, 10, 155 ) as long as it is within the optimal dose such as 1 g, However, at the end of operation before closure, the excessive black tar qel like material can be wiped away and washed with Ringer's feblutJion*
( e) Description of the preferred embodiments of the invention:
As already mentioned previously, the substance powder ool is made by grinding the pure vitamin C tablets into powder. Application of this powder topically to the bleeding area is betber'by spraying the powder topically on the bleeding area. The amount of vitamin C powder needed to spray is proportional to the amount of blood coming out of the vessels. In test tube conditions, it requires 0.1568 g of this* vitamin C powder to coagulate 1 ml of human blood. This λiε the same for normal, liver diseases, cancer, and hemophilia patients. The black coagulation takes place in 6 minutes by shaking the test tube. The description of this sβtuation is made in the evidence of animal ( rats ) experiments and clinical evidence as follows: (f) Rats Experiments
1) Sufficient substance powder 001 can stop massive bleeding of femoral artery within one second when femoral artery is cut off. ( Photograph # 1 : massive bleeding when the femoral artery is cut off ) ( Photogrph # 2: bleeding stops within one second when sufficient powder of interest was poured topically into the bleeding area, in this case of massive active bleeding T did pouring instead of spraying. The amount of the powder needed is proportional to the amount of blood coming out of the vessel. It varies with the rats. Usually 0.1344 g is sufficient to stop bleeding for the femoral artery of the rat which is cut off vithin one second. In the photograph # 2, the black tar gel like material was formed in one second as soon as the powder contacts with the blood . Those white spots indicate the powder that is not yet mixed up with the blood. The black gel forms first on l.he surface of the pond of blood, that stop the fluid moving. If stirring the blood to break through the surface film like πtru that keep the blood fluid from moving when the powder is insuf it will bleed again, but slower than ( much slower ) before • t pouring the powder into the bleeding area; but after adding sufficient powder into the blood, stirring makes the powder molecules well saturated with the hemoglobin and plasma protei molecules and thus forming the concentrated black sticky gel li structure. After 5-6 minutes, when most of the sticky tar like structure is wiped away, it appears there is no bleeding at all. ( Photograph tf 3 ). In the case of capillary bleeding in which one capillary iε cut off, fibout 0. 0112 g of this powder can stop the bleeding within one second, ( Photograph # 4 ). After 1 minute count from adding the powder, it appears there is no more bleeding while wiping away the black tar qel like structure, while in the case of one vein cut off, it needs about 0.0224 g of the powder to stop bleeding, and about after 1 1/2 minutes, it appears there is no more bleeding when the black coagulation is wiped away. ( Photograph t 5 ) . The nostril was cut slightly to bleed ( Photograph # 6 ) in rat the bleeding stop within one second when applying this powder 0.0037 g topically into the bleeding nostril, ( Photograph # 7 ). After injection of histamin into the rat, it induces secretion of gastric acid, open up the stomach ( Photograph * G ), cut the mucosa layer to bleed ( Photograph # 9 ), applying the powder topically to the bleeding area, the black coagulatio formed, but slower than normal, since the secretion dilute the black coagulation. ( Photograph # 10) hup this powder can treat the gastric ulcer bleeding when it is inαested orally. Clinical Evidence.
This powder also help stop massive bleeding in surgery, no matter what kind of diseases the patients suffered from.
Case 1. Age 32, male, scalp tumor excision, massive bleeding when the tumor vas exciεed. ( Photograph # I'l ) Sufficient spraying this powder into the bleeding area also help stop bleerling before it was closed by suture. ( Photo¬ graph # 1>2 ) Case 2. Age 40, female, acute renal failure, Λ-V fistula formation operation, massive bleeding ( Photograph * 1 _ ) The operation of stopping bleeding consiεts of combining the powder with press with gauze. When applying this powder to the bleeding area, those that look black in color indicate the black blood coagulation ( Photograph -ft lj_) ), while those that.are white in color are those the powder does not get mixed up with the blood ( Photograph 1'5 ). At the end of the operation, most of black blood coagulation was wiped out with 4x4 gau/.e, and rinsπrl with Ringer's solution ( Photograph # 1'6 ). It took totally 5 minuteε to stop the bleeding completely. The patient's conditions are especially well, better than without using this powder. Case 3* Age 40, male, skin contracture on the palm, which needs to be removed, and it requires skin graft.-
When the skin graft is removed from the hand,massive bleedi occurs ( Photograph # K7 ) . Qn applying sufficient powder to the bleeding area topically, it appears black coagulation within one second. Bleeding stops nt the same time ac the black coagulation forms. Those that appears white indicate the powder not yet mixed up with the blood. ( Photograph 4 18 ); those that appears more black area indicate the ππre powder mixed up with the blood (Photograph # 19 ), Suture going on ( Photograph * 2 ) Case 4 . Ληe 70 , f ema le , pa raana l abscess exci si on , bl eed i nq when i t i s opened up ( Photograph # 21 ) . When spra yi the powder to the bleeding area, it stop bleeding by forming black blood coagulation immediately. Those that appears white are the powder that are not mixed up with the blood. ( Photograph # 212), Suture going on ( Photograph # 23 ) . Case 5. Age 50, male, paraanal abscess excision. m---εive bleeding when it is opened up ( Photograph * 24 ). On spraying the powder topically to the bleedin area, the black color is formed im edi^ely because o the blood coagulation ( Photograph * 25 ) * The white color is the powder instantly not mixed up- with the blood yet. ( Photograph # 2r ), lastly, inp.Tt the long gauze into the anus. ( Photograph <t 21 ) Case f». Age 30, male, exiraction of tooth, the gum injected b ( Photograph t, 2 _ ). Applying this powder topically to the bleeding area, the bleeding stop within one sec and black blood coagulation forms within one second ( Photograph # 2§ ) . Wipe out the black coagulation in 10 seconds, stop bleeding still persisted ( Photo¬ graph * 3'0 ) Case 7. Age 60, female, chronic hepatitis, has bleeding tende extinction of teeth cause massive bleeding ( Photograp # 3'i ) On applying this powder to the socket of the gu the black coagulation forms within one second, the ble of Ihis socket εic b within one second a~cordingly . ( Photograph * 32 ) Case 0. myself, finger little scratched, slightly bleeds
( Pht.iograph * 33 ) . Upon contact with the powder, l he black color forms within one second or shorter ( Photo PCT/US91/0920
In test, tube con il.ion as mentioned previously, ] m] of human b1.nor! requires 0.15C>fl q of powder to form Ma<-k bloori coa- qulatton by shaking the tube with hand or εtirer machine.
Tl. Lake;; G minutes t.o form the immobile black coaqυlatinπ in the tost t.uhe for normal, liver di.season, colon ranker and hemophilia hlood respectively. ( Photograph ft 3 _ normal blood, colon cancer Photograph # 3* ,, and hemophilia blood
Phuto'jraph i\ 3'7 ) This indicates that, the mechanism of the coagulation by this powder does not involve the coagulation factors. The hemophilia blood ( both prior to adding the powder and after adding powder) are still stored in the freezer here.
This patient's name: Su Jean Wang, Age 25, ma.le, 0.1.
# S 121745233, address: No 5, Su Ming Rd., Lane 100
Nan Tze District, Kaohsiung City / lastly, Stops bleeding in tonsillectomy rat within one second by topical use of th (f). Claims of Utilities of ascorbic acid powder. j
1. Stops bleeding in the nose bleeding in humans within one second, experi nced in my 6 years old dauqhl.er by applying this powder topically χ_ o her bleeding nostril.
' . Stops hlocdinq in any ijury due to any c.-πise, this also be useful for wound bleeding in the war or combat, zone.
'; . S o bleediπq in bleeding tendency patients in surgery or after surgery. Help stop bleeding in Λ-V fistula formation surgery in preparation for hemodialysis.
4. Stops bleeding in massive bleeding in scalp tumor excision. r-. Sto .'* lileediruj in bleeding tendency in paraπal. nbsress orci ion.
6. Stops bleeding in postoperation ( after surq ry ) bleeding Ϊti nni-itii'nm vrnmrl bleeding after rectal anal cancer surgery.
7. Stops bleeding in teeth extraction within one second in bleeding tendency patients when applying this powder topically to the bleeding socket of the gum.
8. Stops bleeding in the hemophilia patients due to injury when applying the powder topically to bleedinq area suf iciently.
9. Stops bleeding in Ob F» Gyn surgery in bleeding tendency

Claims

patients when applying this powder sufficiently to the bleeding area.
IC. Stops bleeding due to injury or bleeding due to any caus
11. Stops gastric ulcer bleeding when ingestion of this powd about 1 g / day orally.
12. Help stop and prevent internal bleeding when taking 1 g of this powder daily orally.
1?. «-np bleeding and help stop bleeding in tonsillectomy
,., . and after tonsillectomy bleeding. . __ ^
EP92901379A 1990-12-06 1991-12-05 Substance that can stop bleeding in surgical, medical and dental uses/substance powder 001 that can stop bleeding during surgery, after surgery, medicine, dentistry or any bleeding due to any causes. Withdrawn EP0644754A4 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US62409490A 1990-12-06 1990-12-06
US624094 1990-12-06
PCT/US1991/009201 WO1992010999A1 (en) 1990-12-06 1991-12-05 Substance that can stop bleeding in surgical, medical and dental uses/substance powder 001 that can stop bleeding during surgery, after surgery, medicine, dentistry or any bleeding due to any causes

Publications (2)

Publication Number Publication Date
EP0644754A1 EP0644754A1 (en) 1995-03-29
EP0644754A4 true EP0644754A4 (en) 1995-12-27

Family

ID=24500629

Family Applications (1)

Application Number Title Priority Date Filing Date
EP92901379A Withdrawn EP0644754A4 (en) 1990-12-06 1991-12-05 Substance that can stop bleeding in surgical, medical and dental uses/substance powder 001 that can stop bleeding during surgery, after surgery, medicine, dentistry or any bleeding due to any causes.

Country Status (5)

Country Link
EP (1) EP0644754A4 (en)
AU (1) AU662505B2 (en)
CA (1) CA2095439C (en)
NO (1) NO930858D0 (en)
WO (1) WO1992010999A1 (en)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2336925A1 (en) * 1975-12-30 1977-07-29 Mouney Guy Dentifrice contg. haemostatic agent, esp. ascorbic acid or salt - has curative action on lesions of gingival epithelium etc.
DE2808572A1 (en) * 1977-03-04 1978-09-07 Shiraimatsu Shinyaku Co HAEMOSTATIC AGENT
WO1987006465A1 (en) * 1986-04-22 1987-11-05 Olav Johan Braenden Anti-cold kit, anti-cold preparation and use thereof
WO1990012572A1 (en) * 1989-04-17 1990-11-01 Duke University Stable ascorbic acid compositions

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1334933A (en) * 1971-02-19 1973-10-24 Ahrens G W Reaction products of caldium ascorbate and preparation containing them
US4959362A (en) * 1983-12-19 1990-09-25 Takeda Chemical Industries, Inc. Pharmaceutical compositions containing certain ascorbic acid derivatives useful in the prophylaxis and treatment of disorders of the circulatory system
US5021452A (en) * 1989-01-09 1991-06-04 The Board Of Regents Of The University Of Washington Process for enhancing wound healing

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2336925A1 (en) * 1975-12-30 1977-07-29 Mouney Guy Dentifrice contg. haemostatic agent, esp. ascorbic acid or salt - has curative action on lesions of gingival epithelium etc.
DE2808572A1 (en) * 1977-03-04 1978-09-07 Shiraimatsu Shinyaku Co HAEMOSTATIC AGENT
WO1987006465A1 (en) * 1986-04-22 1987-11-05 Olav Johan Braenden Anti-cold kit, anti-cold preparation and use thereof
WO1990012572A1 (en) * 1989-04-17 1990-11-01 Duke University Stable ascorbic acid compositions

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
ANTOSZEWSKI Z: "Zastosowanie preparatu Cepevit-K do tamowania krwawien i krwotokow po usunieciu zebow.", POL TYG LEK (POLAND), NOV 20 1972, VOL. 27, NO. 47, PAGE(S) 1861-2, *
DATABASE MEDLINE GURNEY B.F.: "Hemostatic Agents" *
ORAL HYG., vol. 56, no. 7, 1966, pages 78 - 80 *
See also references of WO9210999A1 *

Also Published As

Publication number Publication date
AU9103491A (en) 1992-07-22
AU662505B2 (en) 1995-09-07
WO1992010999A1 (en) 1992-07-09
CA2095439C (en) 1998-12-08
NO930858D0 (en) 1993-03-09
EP0644754A1 (en) 1995-03-29
CA2095439A1 (en) 1992-06-07

Similar Documents

Publication Publication Date Title
AU684850B2 (en) Composition and method for treating blood vessel disorders of the skin using vitamin
US6455067B1 (en) Transdermal patch for nonsteroidal antiinflammatory drug(s)
KR20070090904A (en) Oral compositions for absorption of phosphorus compounds
US5230996A (en) Use of ascorbate and tranexamic acid solution for organ and blood vessel treatment prior to transplantation
Ramasastry Chronic problem wounds
TWI287447B (en) Use of 13-HODE as a regulator of vascular biocompatibility and an inhibitor of cell hyperplasia
Redding Thrombocythemia as a cause of erythermalgia
WO1997039746A1 (en) Method of and composition for treating disorders of the skin using vitamin k
JPH04149126A (en) Pharmaceutical composition for transmucous administration
Sigurdsson et al. Formic acid burn—Local and systemic effects Report of a case
AU662505B2 (en) Substance that can stop bleeding in surgical, medical and dental uses/substance powder 001 that can stop bleeding during surgery, after surgery, medicine, dentistry or any bleeding due to any causes
CN104784193B (en) Pharmaceutical application of protopanaxadiol type notoginsenoside
EP0532706B1 (en) REDUCTION OF CARDIOVASCULAR VESSEL OCCLUSIONS WITH ASCORBATE AND LIPOPROTEIN (a) BINDING INHIBITORS
US5114974A (en) Treatment of atherosclerosis with MgNa2 EDTA
US6783774B1 (en) Substance that stop any kind of bleeding within one second for medical, surgical, postsurgical and dental uses
Lau et al. Wound care in the elderly patient
Vizzardi et al. Nimesulide beta cyclodextrin (nimesulide-betadex) versus nimesulide in the treatment of pain after arthroscopic surgery
Collings et al. Three cases of inoculation of tuberculosis from tattooing
DE3546360C2 (en)
CA3073146C (en) Use of 2-[(3z)-6-fluoro-2-methyl-3-[(4-methylsulfinylphenyl)methylidene]inden-1--yl] acetic acid for making a healing preparation for wounds in patients with diabetes
Herrick et al. CHRONIC ACETANILID POISONINGWITH REPORT OF A CASE DUE TO ABSORPTION OF THE DRUG FROM AN ULCER OF THE LEG.
Clements Manifestations of nutritional deficiency in infants
Walsham Surgery: its theory and practice
Green A Manual of pathology and morbid anatomy
Green Pathology and morbid anatomy

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19940428

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB IT LI LI MC NL SE SE

RBV Designated contracting states (corrected)

Designated state(s): AT BE CH DE DK ES FR GB IT LI LU MC NL SE

A4 Supplementary search report drawn up and despatched

Effective date: 19950626

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH DE DK ES FR GB IT LI LI MC NL SE SE

17Q First examination report despatched

Effective date: 19980803

GRAG Despatch of communication of intention to grant

Free format text: ORIGINAL CODE: EPIDOS AGRA

GRAG Despatch of communication of intention to grant

Free format text: ORIGINAL CODE: EPIDOS AGRA

17Q First examination report despatched

Effective date: 19980803

GRAG Despatch of communication of intention to grant

Free format text: ORIGINAL CODE: EPIDOS AGRA

GRAH Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOS IGRA

APAB Appeal dossier modified

Free format text: ORIGINAL CODE: EPIDOS NOAPE

APBX Invitation to file observations in appeal sent

Free format text: ORIGINAL CODE: EPIDOSNOBA2E

APAF Appeal reference modified

Free format text: ORIGINAL CODE: EPIDOSCREFNE

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

APBT Appeal procedure closed

Free format text: ORIGINAL CODE: EPIDOSNNOA9E

18D Application deemed to be withdrawn

Effective date: 20050701